BMC Complement Altern Med:中药玉屏风散对成年人过敏性鼻炎治疗效果的研究

2017-11-20 AlexYang MedSci原创

中药玉屏风散(YPFS)经常用于过敏性鼻炎(AR)的治疗。之前的综述总结了YPFS的治疗效果和安全性,然而却没有亚群的分析来提供指导临床实践的详细证据。YPFS在中药临床实践指南中推荐作为治疗AR的药物,但是YPFS的治疗时间并没有特别的陈述。最近,有研究人员进行了旨在评估YPFS在治疗成年人AR中的效果和安全性的研究,并利用了最新的证据,并且还在亚群元分析中尝试确定YPFS的使用时间。研究发现,

中药玉屏风散(YPFS)经常用于过敏性鼻炎(AR)的治疗。之前的综述总结了YPFS的治疗效果和安全性,然而却没有亚群的分析来提供指导临床实践的详细证据。YPFS在中药临床实践指南中推荐作为治疗AR的药物,但是YPFS的治疗时间并没有特别的陈述。最近,有研究人员进行了旨在评估YPFS在治疗成年人AR中的效果和安全性的研究,并利用了最新的证据,并且还在亚群元分析中尝试确定YPFS的使用时间。

研究发现,22个随机对照试验(RCTs)总共包括了23个比较。YPFS与安慰剂、药物疗法进行了比较,并且作为一种附加的治疗与药物治疗进行了比较。元分析对4个鼻症状得分和"有效率"是可行的。另外,在YPFS组合治疗之后,4个鼻症状得分表现为降低:鼻痒(MD-0.46, 95% CI[-0.50, -0.42])、打喷嚏(MD-0.41, 95% CI[-0.47, -0.35])、鼻塞((MD-0.46, 95% CI[-0.54, -0.39])和流鼻涕(MD-0.42, 95% CI[-0.58, -0.26])。基于"有效率",元分析表明了YPFS并没有比单独的药物治疗具有更好的效果(RR1.07, 95%CI [0.94, 1.22]),但是YPFS与药物的组合使用要比单独的药物治疗更为有效(RR1.27, 95%CI [1.19, 1.34])。亚群分析表明YPFS并不比第二代抗组胺剂更好(RR1.04, 95%CI [0.90, 1.19])。更进一步的是,当使用时间超过3周时,YPFS的组合治疗效果更好((RR1.15, 95%CI [1.01, 1.32])。另外,YPFS对成年人AR具有很好的耐受性。最后,研究人员指出,中药YPFS对成年人AR是有益的。潜在的益处需要通过更多严谨的RCTs来进行评估。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (12)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-02-27 xuyong536
  3. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-07-03 仁者大医
  5. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-12-06 shizhenshan
  6. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-06-11 w363522449
  7. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2018-09-15 zsyan
  8. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
  9. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]
    2017-11-30 往日如昨

    学习了谢谢分享

    0

  10. [GetPortalCommentsPageByObjectIdResponse(id=1894017, encodeId=6dae189401e0c, content=<a href='/topic/show?id=5e456463eee' target=_blank style='color:#2F92EE;'>#治疗效果#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64637, encryptionId=5e456463eee, topicName=治疗效果)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=373a131, createdName=jxrzshh, createdTime=Sun Feb 04 15:43:00 CST 2018, time=2018-02-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1773187, encodeId=46a11e73187fe, content=<a href='/topic/show?id=5298121e46e' target=_blank style='color:#2F92EE;'>#MPL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12174, encryptionId=5298121e46e, topicName=MPL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10e638510530, createdName=xuyong536, createdTime=Tue Feb 27 17:43:00 CST 2018, time=2018-02-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2046905, encodeId=49d22046905ea, content=<a href='/topic/show?id=6f5294036b1' target=_blank style='color:#2F92EE;'>#过敏性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94036, encryptionId=6f5294036b1, topicName=过敏性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0a8e213, createdName=hongbochen, createdTime=Tue Aug 21 15:43:00 CST 2018, time=2018-08-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1974781, encodeId=0d1119e47817c, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8e886, createdName=仁者大医, createdTime=Tue Jul 03 04:43:00 CST 2018, time=2018-07-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1861180, encodeId=eb97186118092, content=<a href='/topic/show?id=401a23e102' target=_blank style='color:#2F92EE;'>#ALT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2371, encryptionId=401a23e102, topicName=ALT)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ccbd84, createdName=shizhenshan, createdTime=Wed Dec 06 04:43:00 CST 2017, time=2017-12-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1779706, encodeId=c2271e7970621, content=<a href='/topic/show?id=8a4123e754' target=_blank style='color:#2F92EE;'>#Altern#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2377, encryptionId=8a4123e754, topicName=Altern)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1c8c241, createdName=w363522449, createdTime=Mon Jun 11 02:43:00 CST 2018, time=2018-06-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1783546, encodeId=61951e835463c, content=<a href='/topic/show?id=f8db50319a' target=_blank style='color:#2F92EE;'>#Complement#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5031, encryptionId=f8db50319a, topicName=Complement)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=dab8203, createdName=zsyan, createdTime=Sat Sep 15 11:43:00 CST 2018, time=2018-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1688407, encodeId=c237168840e3e, content=<a href='/topic/show?id=af3e6823e4f' target=_blank style='color:#2F92EE;'>#玉屏风散#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=68237, encryptionId=af3e6823e4f, topicName=玉屏风散)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b39b28584634, createdName=ms6519009802973839, createdTime=Mon Feb 26 08:43:00 CST 2018, time=2018-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=265569, encodeId=f4d0265569a1, content=学习了谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c0a61971598, createdName=往日如昨, createdTime=Thu Nov 30 08:52:42 CST 2017, time=2017-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1608271, encodeId=114f16082e19f, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Wed Nov 22 12:43:00 CST 2017, time=2017-11-22, status=1, ipAttribution=)]

相关资讯

中药如何告别“尚不明确”时代

近日,对马兜铃酸与肝癌相关性的热议引发了民众关注。马兜铃酸安全性问题,也将中药的安全问题推向了风口浪尖。

中医中药中国行走进福建:唱响八闽中医药好声音

10月26日,“中医中药中国行——福建省中医药健康文化推进行动”暨“晋江市名医工作站”启动仪式在福建省泉州晋江市举行。

炸开锅!这些药致肝癌?

近日,一篇关于马兜铃酸的论文,在权威医学期刊《Science Translation Medicine》上,并荣登该杂志封面。这篇探讨马兜铃酸与肝癌关系的论文,瞬间在全社会炸开了锅。 ▍天造地设的“理想毒药”? 说起马兜铃酸,早在1993年,马兜铃酸就作为肾衰竭元凶被人们所认识,只需要130毫克的马兜铃酸就可以导致肾病。 而本次上封面的,是来自新加坡和台湾的研究人员的

国家卫计委:发展中医药特色医养 鼓励社会资本进入

11月15日,国家卫生计生委发布了《“十三五”健康老龄化规划重点任务分工》的通知(下称《通知》),明确指出了包含国家卫生计生委等在内在13部门关于“十三五”健康老龄化规划重点任务的分工。

中药攻占全球,80个国家动起来了

“太激动人心了!中药攻占全球市场,我们有希望!”出席 “世界中医药服务贸易联合会”成立大会的一位代表发出了内心的感慨。日前,中国医药物资协会在加勒比海洋量子号游轮上主办的第十二届中国成长型医药企业发论坛暨世界中医药服务贸易推进大会上,5000名医药人士出席。在这次活动上,自全球80多个国家和地区的中医药行业代表共同发起成立了世界中医药服务贸易联合会。在中国倡导的“一带一路”获世界瞩目背景下,中药通

中药注射剂、生化药大检查!

昨日(11月10日),黑龙江省药监局印发《黑龙江省2017年生化药品及中药注射剂专项检查工作方案》(以下简称方案),将对全省所有生化药品及中药注射剂药品生产企业进行检查。